{
    "2019-01-23": [
        [
            {
                "time": "2018-01-23",
                "original_text": "招商银行2018年净利润升14.84%至805.6亿元",
                "features": {
                    "keywords": [
                        "招商银行",
                        "净利润",
                        "增长",
                        "2018年"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-24",
                "original_text": "复星医药：实体瘤治疗新药临试获美国FDA批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "实体瘤",
                        "新药",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-24",
                "original_text": "复星医药：子公司获美国FDA药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-24",
                "original_text": "复星医药(02196.HK)：FCN-437c用于实体瘤治疗获美国FDA临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-437c",
                        "实体瘤",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}